Bristol Myers Squibb has completed the previously announced acquisition of Turning Point Therapeutics, for a total consideration of $4.1bn in cash.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,